Mission Therapeutics concludes clinical assessment for lead DUB inhibitor
Safety, tolerability and pharmacokinetic endpoints for MTX652 have been successfully met
Read More
Tag: DUB
Almac links with MSD in research collaboration
Almac and MSD will initially work together in a two-year joint research programme
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
